학술논문
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
Document Type
Article
Author
Hammitt, Laura L.; Quinn, Dean; Janczewska, Ewa; Pasquel, Francisco J.; Tytus, Richard; Reddy, K. Rajender; Abarca, Katia; Khaertynova, Ilsiyar M.; Dagan, Ron; Dawson, Rachel; McCauley, Jennifer; Shekar, Tulin; Fu, Wei; Pedley, Alison; Sterling, Tina; Tamms, Gretchen; Musey, Luwy; Buchwald, Ulrike K.
Source
Human Vaccines & Immunotherapeutics; 2023, Vol. 19 Issue 1, p1-11, 11p
Subject
Language
ISSN
21645515